Eloxx Pharmaceuticals Names New CEO and CFO in Board Overhaul

Eloxx Pharmaceuticals Inc. (ELOX) appointed Sumit Aggarwal president and chief executive officer and elected David Epstein chief financial officer, both effective June 1 2026, according to an 8-K filed with the SEC on that date.

The filing discloses the departure or election of directors or principal officers under Item 5.02, unregistered sales of equity securities under Item 3.02, material modification to rights of security holders under Item 3.03, and amendments to articles of incorporation or bylaws under Item 5.03.

It also includes financial statements and exhibits under Item 9.01. The company did not disclose any cited cause for the leadership transition.

Prior to the filing Eloxx operated without Aggarwal or Epstein in those roles. The new officers assume their positions immediately on June 1 2026. The company also altered shareholder rights and updated its governing documents on the same date.

The leadership change triggers standard SEC reporting obligations already satisfied by the 8-K. Any future equity compensation grants to the new executives will require separate Form 4 filings within two business days of the transactions. Amendments to the certificate of incorporation may require shareholder ratification at the next annual meeting depending on state law and the company's bylaws.

The unregistered equity sales reported under Item 3.02 will necessitate updated capitalization tables in the company's next quarterly or annual report.

This is the first leadership transition reported by Eloxx since its prior executive team was in place. The company, which has focused on rare disease therapeutics, now operates under new principal officers while carrying out recent unregistered financing and corporate governance updates detailed in the same filing.